First Trust Advisors LP grew its stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 197.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,191 shares of the biotechnology company’s stock after buying an additional 89,724 shares during the period. First Trust […]
BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 170,205 shares of the biotechnology company’s stock after purchasing an additional 11,028 shares during the […]
Raymond James & Associates lowered its holdings in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 0.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,911 shares of the biotechnology company’s stock after selling 529 shares during the quarter. Raymond […]
California Public Employees Retirement System trimmed its holdings in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,450 shares of the biotechnology company’s stock after selling 8,870 shares during the period. California Public Employees […]
Skandinaviska Enskilda Banken AB publ bought a new position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 9,679 shares of the biotechnology company’s stock, valued at approximately $1,639,000. Several other hedge funds have also modified […]